SpliSense Raises $13 Million to Advance RNA-Based Treatments
SpliSense, a biotechnology firm based in Jerusalem, Israel, has secured $13 million in an undisclosed funding round. This investment was led by the Cystic Fibrosis Foundation. SpliSense focuses on developing RNA-based therapies, specifically using Antisense Oligonucleotides (ASOs), to address the root causes of pulmonary diseases by restoring and modifying protein functionality.
Leadership and Vision
Gili Hart, the Chief Executive Officer of SpliSense, is at the forefront of this innovative approach to treating pulmonary conditions. The company aims to tackle diseases that currently lack effective treatments, leveraging their transformative RNA-based solutions.
Strategic Use of Funds
While specific plans for the newly raised capital have not been disclosed, it is anticipated that the funds will support further development and clinical trials of SpliSense's therapies. Investment in research and development is crucial for advancing their pipeline of treatments targeting untreatable pulmonary diseases.
Lead Investor: Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation, known for its commitment to funding research and development in the field of cystic fibrosis, has taken the lead in this round of funding. The foundation's involvement signals a strong endorsement of SpliSense's potential to make significant strides in pulmonary disease treatment.
Looking Ahead
With this fresh injection of capital, SpliSense is well-positioned to continue its pioneering work in RNA-based therapies. The support from the Cystic Fibrosis Foundation underscores the importance of innovative approaches in tackling challenging medical conditions. As the company moves forward, its developments will be closely watched by both the medical community and potential investors.